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Abstract
Introduction: The US Food and Drug Administration approved a 23 mg daily dose of donepezil for treatment of
moderate to severe Alzheimer’s disease (AD) based on outcomes from a large trial comparing the 23 mg/day dose
with the standard 10 mg/day dose. Results from this study indicated that after 24 weeks, donepezil 23 mg/day
provided significant cognitive benefits over donepezil 10 mg/day, measured using the Severe Impairment Battery
(SIB). In the analyses reported herein, we further characterize the range of cognitive domains impacted by
treatment with donepezil 23 mg/day.
Methods: A post hoc analysis was conducted using data from a 24-week, randomized, double-blind trial
comparing donepezil 23 mg/day versus 10 mg/day in 1,467 patients with moderate to severe AD (baseline Mini-
Mental State Examination (MMSE) score 0 to 20). Changes from baseline to week 24 in the nine SIB domain scores
were analyzed in the intent-to-treat (ITT) population (baseline MMSE 0 to 20), in patients with more severe baseline
AD (MMSE 0 to 16), and in severity strata based on baseline MMSE scores (0 to 5, 6 to 10, 11 to 15, 16 to 20).
Results: In the ITT population, changes in six of the nine SIB domains favored donepezil 23 mg/day over
donepezil 10 mg/day. LS mean treatment differences were significant for the language, visuospatial ability, and
construction domains. In the more advanced cohort of patients (MMSE 0 to 16 at baseline), LS mean treatment
differences were statistically significant favoring donepezil 23 mg/day in five of the nine domains: language,
memory, visuospatial ability, attention, and construction. Descriptive analysis of LS mean changes in SIB domain
scores in the four baseline severity strata showed variable patterns of response; overall, cognitive benefits of
donepezil 23 mg/day were greatest in patients with MMSE scores of 0 to 15.
Conclusions: These results suggest that donepezil 23 mg/day provides benefits over 10 mg/day across a range of
cognitive domains. The magnitude of benefit and domains impacted varied depending on the stage of AD;
significant benefits with higher dose donepezil were most apparent at more advanced stages of AD and were
most prominent in the language domain.
Introduction
Alzheimer’s disease (AD) is a progressive neurodegen-
erative disorder affecting more than 5 million people in
the United States and 35 million people worldwide [1].
Based on the latest estimates, more than half of these
individuals would be classified as having moderate or
severe AD [2]. These more advanced stages of the disease
can last for up to a decade [3,4], placing a great burden
on families and caregivers and resulting in substantial
health care costs [1].
Cognitive dysfunction in the early stages of AD has
been well studied using clinical trial assessment scales
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such as the Alzheimer’s Disease Assessment Scale
(ADAS) [5,6], a valid and reliable tool for evaluating
cognition in patients at less advanced stages of the dis-
ease; however, when patients progress to moderate to
severe stages of AD, this scale is no longer effective or
reliable. Floor effects, in particular, limit its usefulness
in measuring cognitive capabilities or changes in cogni-
tive function related to therapy [7]. The Severe Impair-
ment Battery (SIB) was originally developed more than
20 years ago to assess cognition in patients with more
advanced AD [8-11]. It uses one-step conversational
commands presented with gestural cues, which
enhances its utility in patients with profound impair-
ment in their ability to communicate. The SIB is a reli-
able and sensitive assessment tool when used in patients
progressing from moderate to severe AD. It has been
widely used and validated as a measure of cognitive
function in several clinical trials [3,7,12-15]. The SIB
was designed to assess cognitive function across nine
domains: language, memory, praxis, visuospatial ability,
attention, orientation, social interaction, construction,
and orienting to name [8].
Donepezil, a selective, reversible acetylcholinesterase
inhibitor, is approved in the US for the treatment of AD
in the moderate to severe stages. In addition to standard
5 mg and 10 mg daily doses, the US Food and Drug
Administration (FDA) has approved the use of a higher
daily dose of donepezil (23 mg) to treat patients with
moderate to severe AD [16]. Approval of the 23 mg
daily dose was based on outcomes from a large, rando-
mized clinical trial comparing donepezil 23 mg/day with
donepezil 10 mg/day [17]. Results from this study indi-
cated that after 24 weeks of treatment donepezil 23 mg/
day provided statistically significant incremental cogni-
tive benefits over donepezil 10 mg/day, as measured
using the SIB. For the global function co-primary end
point (Clinician’s Interview-Based Impression of
Change-plus caregiver input (CIBIC-plus)), no statisti-
cally significant incremental benefits of donepezil 23
mg/day over 10 mg/day were observed. A subsequent
post hoc analysis, focused on evaluating the possible dif-
ferential effects of the two donepezil doses on language
function, indicated that the overall cognitive benefits of
donepezil 23 mg/day over 10 mg/day were driven at
least in part, by language benefits [18]. Herein we report
the results of additional post hoc analyses of data from
the trial of donepezil 23 mg/day versus donepezil 10
mg/day to further characterize the range of cognitive
domains impacted by treatment with donepezil 23 mg/
day. In order to investigate treatment responses across a
spectrum of disease severity, we studied effects in the
overall intent-to-treat (ITT) population (all Mini-Mental
State Examination (MMSE) scores 0 to 20), in a cohort
of patients with more severe baseline impairment
(MMSE 0 to 16 at baseline) as determined in the original
study report [17], and in further severity strata (MMSE
0 to 5, 6 to 10, 11 to 15, and 16 to 20).
Materials and methods
Study design
Methods used in the original clinical trial have been
described in detail previously [17]. In brief, this was a
24-week, double-blind, parallel group, global study
including 1,467 patients aged 45 to 90 years, who were
diagnosed with moderate to severe AD (baseline MMSE
scores 0 to 20) and who had been receiving a stable
dose of donepezil 10 mg/day for at least 3 months.
Patients were randomized in a ratio of 2:1 to increase
their daily dose of donepezil to 23 mg/day, or to con-
tinue taking their existing dose of 10 mg/day. The pre-
specified co-primary efficacy measures from the original
study were change from baseline in SIB total score (cog-
nition) and the CIBIC-plus global change scores at week
24. The protocol and informed consent form for the ori-
ginal trial were approved by the independent ethics
committee and institutional review board of each inde-
pendent research site and conformed to the principles
of the World Medical Association Declaration of Hel-
sinki and all local regulations. Written informed consent
was obtained from each patient where possible, or from
the patient’s legal guardian or representative. If a patient
was unable to provide written consent, he or she was
required to provide verbal agreement to participate in
the study, with documentation of this assent noted in
the study record [17].
SIB scale
The SIB includes 40 items divided across the nine cogni-
tive domains (Figure 1) [8,10]. The subdomains of the
SIB are weighted differently, with language making up
the largest proportion (Figure 1). The total SIB score for
each patient consists of the sum of all responses on the
nine SIB domains and ranges from 0 (worst score) to 100
(best score). SIB assessments were performed at screen-
ing, baseline, and weeks 6, 12, 18, and 24.
Analyses
Post hoc analysis of changes from baseline to week 24 in
individual SIB domain scores was performed in the over-
all ITT population (all MMSE scores 0 to 20), in the
cohort of patients with more severe baseline impairment
(MMSE 0 to 16 at baseline), and in further severity strata
based on baseline MMSE (0 to 5, 6 to 10, 11 to 15, and
16 to 20).
Analysis of changes in SIB domain scores at week 24
was performed using an analysis of covariance model
with country, treatment, and baseline as interaction
terms. For efficacy analysis in the patient populations and
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subpopulations, missing SIB values were imputed by the
last observation carried forward (LOCF) method.
Standardized effect sizes for the nine SIB domains were
calculated for the overall patient population and subpo-
pulations (overall ITT, MMSE 0 to 16, MMSE 0 to 5,
MMSE 6 to 10, MMSE 11 to 15, MMSE 16 to 20) by
dividing the treatment differences of least squares (LS)
means by the pooled SDs. A positive effect size means
that on average donepezil 23 mg performed better than
donepezil 10 mg, while the reverse is true for a negative
effect size. For positive effect sizes, the higher the effect
size, the greater the difference in treatment effect
between the donepezil 23 mg and donepezil 10 mg
groups. The pooled SD is the SD of change from baseline




In total, 1,467 patients were randomized to donepezil 23
mg/day (n = 981) and donepezil 10 mg/day (n = 486) in
the original trial. Of these, 1,371 patients (909 patients
receiving donepezil 23 mg/day and 462 receiving done-
pezil 10 mg/day) comprised the overall ITT population.
Patient baseline demographics and clinical characteris-
tics were similar for both donepezil treatment groups, as
has been previously reported [17,18]. Relevant baseline
demographics and characteristics are shown for the ITT
population in Table 1. Baseline disease severity, as
assessed using the MMSE and SIB, was comparable
between the two treatment groups. There were no nota-
ble differences in individual SIB domain baseline scores
(MMSE 0 to 20) (Table 1).
Analyses: treatment effects on individual domains of the
SIB scale
Treatment effects in the overall ITT population (MMSE 0 to
20)
For the overall ITT population, scores in eight of the
nine individual SIB domains improved from baseline
with donepezil 23 mg/day, the exception being orienting
to name scores, which were relatively unchanged (Figure
2). No decline from baseline was seen in individual SIB
domain scores among the patients receiving donepezil
23 mg/day. In the donepezil 10 mg/day treatment
group, scores on five of the SIB domains (memory,
praxis, attention, orientation, and social interaction)
were improved from baseline, scores on two (construc-
tion and orienting to name) were stable, and scores on
two (language and visuospatial ability) declined. Changes
in SIB scores numerically favored patients treated with
donepezil 23 mg/day over donepezil 10 mg/day for six
of the nine SIB domains (language, memory, praxis,
visuospatial ability, attention, and construction). These
Figure 1 Severe Impairment Battery domains and scale points allocated. SIB, Severe Impairment Battery.
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treatment differences were statistically significant in favor
of donepezil 23 mg/day for three domains (language
(P <0.001), visuospatial ability (P <0.05), and construction
(P <0.01)).
Larger effect sizes indicating greater benefits with
donepezil 23 mg/day over donepezil 10 mg/day were
observed for the language, construction, visuospatial
ability, praxis, memory, and attention domains (Table
2); these domains encompass the majority of items on
the SIB. The greatest effect in favor of 23 mg was seen
in the language domain (effect size = 0.191), which com-
prises 46 of 100 points on the total SIB scale. Treatment
differences and effect sizes were negligible for the orien-
tation, social interaction, and orienting to name
domains.
Treatment effects in the cohort with more severe baseline
impairment (MMSE 0 to 16)
In the original clinical trial [17], post hoc sensitivity ana-
lyses of the impact of baseline disease severity on treat-
ment response were conducted in a cohort of patients
with baseline MMSE scores from 0 to 16 (more severe
impairment). In the current study, in the same severity
strata, improvement from baseline with donepezil 23 mg/
day was demonstrated in six of the nine individual SIB
domain scores (language, memory, praxis, attention,
orientation, and construction), whereas scores for social
interaction, visuospatial ability, and orienting to name
were stable (Figure 2). No decline from baseline in indivi-
dual SIB domain scores was seen among the patients
receiving donepezil 23 mg/day. Patients treated with
donepezil 10 mg/day had improved scores from baseline
in three domains (memory, attention, and orientation),
scores on two were stable (social interaction and orienting
to name), and scores on four declined (language, praxis,
visuospatial ability, and construction). In this more
severely impaired cohort, changes in five of the nine SIB
domains comparing donepezil 23 mg/day to donepezil 10
mg/day were statistically significant (language (P <0.001),
memory (P <0.05), visuospatial ability (P <0.05), attention
(P <0.05), and construction (P <0.01)).
In this cohort of patients with more severe baseline
impairment, the largest treatment effect was seen in the
language domain (effect size = 0.253) (Table 2). Effect
sizes also demonstrated similar cognitive benefits of
donepezil 23 mg over 10 mg in the domains of con-
struction, visuospatial ability, memory, attention, and
praxis. As was seen in the overall patient population,
treatment differences and effect sizes were negligible for
the orientation, social interaction, and orienting to name
domains. In all domains except orienting to name, effect
sizes were greater in this cohort versus the overall ITT
population.
Treatment effects in baseline severity strata
The LS mean changes in SIB domain scores from base-
line to end point were also evaluated descriptively for
each of the four baseline severity strata (Figure 3). This
subgroup analysis revealed variable patterns of response.
Patients in each of the two more severe strata (MMSE 0
to 5 and 6 to 10) tended to exhibit the greatest treat-
ment differences in favor of donepezil 23 mg/day for the
domains of social interaction, memory, language, praxis,
visuospatial ability, and construction. Patients in the two
moderate strata (MMSE 11 to 15 and 16 to 20) tended
to show smaller between-treatment differences, and in
some domains (visuospatial ability, construction, and
orienting to name) no between-treatment differences
were seen in these strata. Overall, the descriptive analy-
sis across the four severity strata indicated that the cog-
nitive benefits of donepezil 23 mg/day compared with







Mean (SD) 73.8 (8.6) 73.8 (8.5)
(n = 462) (n = 909)
Gender
Male, n (%) 175 (37.9) 335 (36.9)
Female, n (%) 287 (62.1) 574 (63.1)
Total patients, n 462 909
ADCS-ADL-sev
Mean (SD) 34.5 (11.2) 34.1 (10.9)
(n = 461) (n = 908)
CIBIS-plus
Mean (SD)
4.38 (0.89) 4.42 (0.85)
(n = 461) (n = 904)
MMSE
Mean (SD) 13.1 (4.7) 13.1 (4.99)
(n = 462) (n = 908)
SIB
Mean (SD) 75.6 (16.3) 74.2 (17.6)
(n = 462) (n = 907)
Individual SIB domain scores, mean (SD):
Language 36.7 (8.40) 36.2 (9.02)
Memory 8.5 (3.03) 8.2 (3.24)
Praxis 5.5 (2.33) 5.4 (2.45)
Visuospatial ability 6.5 (2.04) 6.3 (2.34)
Attention 4.3 (1.65) 4.2 (1.66)
Orientation 3.7 (1.45) 3.7 (1.45)
Social 5.3 (1.14) 5.3 (1.06)
Construction 3.4 (1.16) 3.3 (1.25)
Orienting to name 1.7 (0.59) 1.6 (0.60)
Total patients, n 462 907
ADCS-ADL-sev, Alzheimer’s Disease Cooperative Study-Activities of Daily Living
Inventory, severe version; CIBIS-plus, Clinician’s Interview-Based Impression of
Severity-plus caregiver input; MMSE, Mini-Mental State Examination; SIB,
Severe Impairment Battery; SD, standard deviation.
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donepezil 10 mg/day were greatest in patients with
MMSE scores of 0 to 15.
The domains most positively impacted by treatment
with donepezil 23 mg/day for the most severely impaired
patient stratum (MMSE 0 to 5) were the praxis, language,
construction, and memory domains (Table 2); treatment
benefits to a lesser degree were also seen in the social
interaction, visuospatial ability, and attention domains.
Effect sizes were minimal in the orientation and orienting
to name domains. For the MMSE 6 to 10 stratum, treat-
ment effects were greatest in the language, visuospatial
ability, and construction domains but relatively small for
the remaining domains. The effect size data generally
showed smaller differences in treatment effect between
the 23 mg/day and 10 mg/day groups for the MMSE 11 to
15 and 16 to 20 patient strata. In the MMSE 11 to 15
group, the greatest effects were in the language, attention,
and orientation domains, with lesser effects on memory,
praxis, and construction, and no effect on the remaining
domains. For the more moderately impaired patient stra-
tum (MMSE 16 to 20), all the domains except orientation,
social interaction, and orienting to name were minimally
but positively affected by donepezil 23 mg/day treatment.
Discussion
The current post hoc analysis was conducted to further
characterize the nature of the cognitive benefits seen in
the primary study of donepezil 23 mg/day versus
Figure 2 Change from baseline in Severe Impairment Battery subdomain scores at week 24 (last observation carried forward). *P
<0.001, †P <0.05, ‡P <0.01. (A) Overall ITT population (MMSE 0 to 20). (B). MMSE 0 to 16. ITT, intent to treat; MMSE, Mini-Mental State
Examination; LS, least squares.
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Table 2 Standardized effect sizes by individual SIB domains for the overall study population and patient subgroups
(intent-to-treat population, last observation carried forward)
Severe Impairment
Battery (SIB) domain
Mini-Mental State Examination score
0 to 20 0 to 16 0 to 5 6 to 10 11 to 15 16 to 20
Language LS mean treatment difference 0.903 1.310 (0.63 to 2.602 1.686 0.691 0.141
(95% CI)* (0.38 to 1.43) 1.99) (0.17 to 5.04) (0.25 to 3.12) (-0.19 to 1.57) (-0.40 to 0.68)
Standardized effect size† 0.253 (5.171) 0.152 0.045
(pooled SD) 0.191 0.396 0.289 (4.558) (3.150)
(4.736) (6.571) (5.828)
Memory LS mean treatment difference 0.269 0.421 0.871 (-0.19 0.249 (-0.44 0.237 (-0.22 to 0.087 (-0.32 to
(95% CI)* (-0.02 to 0.56) (0.07 to 0.77) to 1.93) to 0.94) 0.69) 0.50)
Standardized effect size† 0.155 (2.711) 0.304 (2.863) 0.086 (2.893) 0.093 (2.534) 0.035 (2.469)
(pooled SD) 0.101
(2.675)
Praxis LS mean treatment difference 0.216 0.252 (-0.02 to 0.854 (0.10 to 0.238 (-0.34 0.099 (-0.27 to 0.108 (-0.16 to
(95% CI)* (-0.00 to 0.43) 0.52)0.115 1.61)0.415 to 0.81)0.099 0.47)0.046 0.37)0.061
Standardized effect size† (2.192) (2.060) (2.417) (2.148) (1.753)
(pooled SD) 0.104
(2.077)
Visuospatial ability LS mean treatment difference 0.195 0.311 0.576 (-0.36 0.506 (-0.04 -0.004 (-0.30 0.049 (-0.16 to
(95% CI)* (0.00 to 0.39) (0.06 to 0.56) to 1.51)0.221 to 1.05)0.230 to 0.29)-0.002 0.26)
Standardized effect size† 0.161 (1.934) (2.603) (2.198) (1.634) 0.039 (1.284)
(pooled SD) 0.110
(1.772)
Attention LS mean treatment difference 0.123 0.179 0.211 (-0.33 0.098 (-0.26 0.240 (0.02 to 0.032 (-0.17 to
(95% CI)* (-0.02 to (0.01 to 0.35) to 0.76)0.141 to 0.46)0.064 0.46)0.195 0.23)0.026
Standardized effect size 0.26)0.093 0.132 (1.500) (1.516) (1.233) (1.231)
(pooled SD) (1.326) (1.357)
Orientation LS mean treatment difference 0.038 (-0.10 0.056 (-0.11 to -0.028 (-0.45 -0.003 (-0.31 0.152 (-0.08 to -0.033 (-0.24
(95% CI)* to 0.18)0.028 0.22)0.041 to 0.40)-0.024 to 0.30)-0.002 0.38)0.105 to 0.18)-0.025
Standardized effect size† (1.354) (1.367) (1.160) (1.352) (1.445) (1.290)
(pooled SD)
Social interaction LS mean treatment difference -0.003 (-0.10 0.028 0.423 (-0.16 -0.077 (-0.35 -0.071 (-0.22 -0.064 (-0.18
(95% CI)* to 0.10)-0.003 (-0.10 to to 1.00)0.273 to 0.20)-0.065 to 0.08)-0.075 to 0.05)-0.084
Standardized effect size† (1.012) 0.16)0.026 (1.547) (1.189) (0.956) (0.762)
(pooled SD) (1.086)
Construction LS mean treatment difference 0.139 (0.04 to 0.176 (0.04 to 0.505 (0.04 to 0.220 (-0.10 0.053 (-0.10 to 0.062 (-0.04 to
(95% CI)* 0.24)0.146 0.31)0.168 0.97)0.395 to 0.54)0.166 0.21)0.061 0.16)0.097
Standardized effect size† (0.951) (1.045) (1.280) (1.324) (0.863) (0.642)
(pooled SD
Orienting to name LS mean treatment difference -0.026 (-0.08 -0.024 (-0.10 to 0.050 (-0.22 -0.043 (-0.18 -0.046 (-0.14 -0.023 (-0.10
(95% CI)* to 0.03)-0.042 0.05)-0.037 to 0.32)0.065 to 0.10)-0.063 to 0.05)-0.080 to 0.05)-0.038
Standardized effect size† (0.635) (0.642) (0.771) (0.690) (0.579) (0.601)
(pooled SD)
Total SIB LS mean treatment difference 2.152 (1.06 to 3.141 (1.74 to 6.048 (1.04 3.258 (0.30 to 1.697 (-0.11 to 0.504 (-0.67 to
(95% CI) 3.24)0.218 4.54)0.296 to11.05)0.460 6.21)0.273 3.51)0.181 1.68)0.076
Standardized effect size† (9.864) (10.619) (13.150) (11.941) (9.376) (6.657)
(pooled SD)
*Difference between donepezil 23 mg/day and 10 mg/day treatment groups for the score change from baseline to week 24; †positive standardized effect sizes
represent superiority of donepezil 23 mg/day dose over 10 mg/day dose. LS, least squares.
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donepezil 10 mg/day [17], and to assess the range of
patients experiencing benefits from a transition from
donepezil 10 mg/day to 23 mg/day. In the full study
population, statistically significant incremental benefits
of donepezil 23 mg/day over donepezil 10 mg/day were
observed for the domains of language, visuospatial abil-
ity, and construction (MMSE 0 to 20). In the cohort
of patients with more severe baseline disease (MMSE
Figure 3 Severe Impairment Battery domain scores - change from baseline to week 24, stratified by baseline Mini-Mental State
Examination subgroups (intent-to-treat populations, last observation carried forward). MMSE, Mini-Mental State Examination; LS, least squares.
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0 to 16), significant clinical treatment benefits in favor
of donepezil 23 mg/day were again evident in the
domains of language, visuospatial ability, and construc-
tion, but also in the domains of memory and attention.
Across both populations, scores declined with 10 mg on
the domains of language, praxis, visuospatial ability, and
construction, but scores on these domains were either
improved or stabilized with 23 mg. Moreover, based on
the standardized effect sizes analysis, the benefits of
23 mg over 10 mg were greater in the 0 to 16 cohort
than the overall ITT population for most domains,
further indicating that the transition from 10 to 23 mg
may be most beneficial at advanced stages of AD. Done-
pezil 23 mg provided benefits over donepezil 10 mg on
the majority of SIB domain scores across the four base-
line severity strata. These benefits were numerically
greatest in the patients with the most severe disease at
baseline (MMSE 0 to 5) for social interaction, memory,
language, praxis, visuospatial ability, and construction.
Overall, most incremental benefits of treatment with
donepezil 23 mg/day over 10 mg/day were seen in
patients with more advanced baseline disease (MMSE
0 to 15). These findings suggest that despite the advan-
cing cholinergic deficit in AD, increasing levels of choli-
nesterase inhibition may help maintain certain cognitive
abilities as the disease progresses [19]. It may be the
case that while patients with early-stage AD achieve suf-
ficient response from lower-dose acetylcholinesterase
inhibitors, patients with more advanced AD require
higher doses to achieve an optimal response.
The investigation of subdomains on the SIB scale and
the identification of specific areas of treatment effects
have important clinical implications. The calculated
standardized effect sizes demonstrated that donepezil
23 mg/day showed substantial benefits over 10 mg/day
on a broad range of cognitive domains, specifically, lan-
guage, construction, visuospatial ability, praxis, memory,
and attention, and these benefits were evident in the
overall moderate to severe study population (MMSE
0 to 20) as well as the patient cohort with more severe
baseline disease (MMSE 0 to 16). However, for the most
severely impaired patient group (MMSE 0 to 5), the
greatest benefits of comparable magnitude were seen in
the domains of praxis, language, and construction; a
notable effect on memory and social interaction was
also observed. Patients in the more moderate MMSE
subgroups had smaller treatment effect sizes generally.
These results suggest that treatment with donepezil
23 mg/day may help preserve patients’ ability to com-
municate verbally as they move from moderate to more
severe disease. Language improvements, together with
improvements in construction and visuospatial ability
associated with the donepezil 23 mg/day dose, may
translate into everyday benefits for patients with AD in
their ability to communicate and perform activities of
daily living.
Previous studies have examined the impact of drug
therapy on SIB domain scores in patients with moderate
to severe AD. Pooled data from four clinical trials invol-
ving patients with moderate or severe AD treated with
donepezil 5 mg/day or 10 mg/day or placebo (n = 904;
MMSE 1 to 17) demonstrated that donepezil treatment
provided significant improvement compared with pla-
cebo on seven of the nine SIB domain scores (excluding
social interaction and orienting to name) [20]. The
observation that the greatest benefit of donepezil
10 mg/day over placebo was in language, praxis, mem-
ory, and visuospatial ability domains was supported
by the results of our study; data for the MMSE 0 to 16
population show that the greatest benefits of donepezil
23 mg/day over 10 mg/day were seen in the language,
visuospatial ability, memory, and construction domains.
Treatment benefit was seen in the praxis domain but to
a lesser degree. Furthermore, in the pooled analysis by
Cummings and colleagues [20], scores on almost all
subdomains were improved from baseline to month 6
with donepezil 10 mg/day among the MMSE 1 to 5 and
6 to 9 groups. However, in the current study, scores on
the same domains declined in the MMSE 0 to 5 and 6
to 10 groups with donepezil 10 mg/day (with the excep-
tion of attention and orientation). A factor contributing
to this difference is that donepezil was initiated at the
start of the donepezil 10 mg/day versus placebo study,
whereas patients in the current study had been receiving
donepezil 10 mg for a minimum of 3 months (with a
mean duration of 2 years on donepezil 10 mg) at study
initiation. Therefore, patients in the current study might
be less likely to experience a further increase in sympto-
matic benefits from continued donepezil 10 mg/day
treatment.
A study of galantamine therapy in patients with severe
AD (baseline MMSE scores of 5 to 12; n = 407) demon-
strated improvement in several SIB domains, with signif-
icant treatment benefit compared with placebo for the
domains of memory (P = 0.006), praxis (P = 0.010), and
visuospatial ability (P = 0.002) [21]. Although treatment
effect sizes were not provided in this study, the greatest
numerical benefits of galantamine over placebo seemed
to be in the domains of language, praxis, memory, and
visuospatial ability, as was the case in the study by Cum-
mings and colleagues [20]. Studies of memantine treat-
ment have also shown significant benefits compared
with placebo for the SIB subdomains [12,13,22]. A post
hoc analysis of data from six randomized, double-blind,
6-month studies of patients with moderate to severe AD
showed a significant benefit of memantine treatment,
compared with placebo, for the SIB subdomains of
language (P <0.05), memory (P <0.05), orientation
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(P <0.01), praxis (P <0.001), and visuospatial ability
(P <0.01) [22]. These studies demonstrate that patients
with moderate to severe AD can be assisted with a vari-
ety of types of pharmacotherapy. There are differences
between these prior studies and our study. Most impor-
tantly, the previous studies reported the efficacy of active
drug versus placebo, whereas our results compare two
doses of active drug. This may have affected comparisons
as patients receiving placebo may decline more rapidly
than those taking 10 mg/day donepezil. Second, effect size
data are often not available from these prior studies.
Although the current analysis was designed to further
investigate cognitive outcomes with donepezil 23 mg/
day, the pivotal study that provided the data for this
analysis also assessed the safety and tolerability of done-
pezil 23 mg/day compared with 10 mg/day over 24
weeks [17]. Subjects transitioning to higher-dose done-
pezil experienced an increase in gastrointestinal events,
with more nausea and vomiting. These side effects
occurred more frequently during the first month after
starting treatment and, for patients who adhered to
treatment, were relatively infrequent thereafter. Clinical
benefits of donepezil 23 mg/day, in terms of cognitive
changes such as those discussed herein, should be care-
fully assessed on a patient-by-patient basis together with
the related side effect profile, to allow physicians to
determine whether patients are benefiting from the
higher dose of donepezil.
The limitations of this post hoc study should be con-
sidered when interpreting the results. Data for the LS
mean treatment difference should be interpreted with
caution, as the number of total possible points varies by
SIB domain. The study was not powered for differences
in subdomains and for this reason the statistical signifi-
cance may be secondary to the consistent pattern of the
findings.
Conclusions
The results of this post hoc analysis suggest that done-
pezil 23 mg/day provides benefits over 10 mg/day across
a range of cognitive domains in patients with moderate
to severe AD. Although the magnitude of these benefits
and the specific domains that were impacted varied
depending on the severity of AD, the analyses indicated
that significant incremental benefits with the higher
donepezil dose (23 mg/day) were most prominent in the
language domain and most apparent in patients at more
advanced stages of the disease.
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